Novartis ofatumumab demonstrates superiority versus Aubagio in two head-to-head Phase III multiple sclerosis studies
[caption id="attachment_9277" align="alignnone" width="747"] Press Release[/caption]
In ASCLEPIOS I and II, ofatumumab (OMB157) met primary endpoints to reduce the annualized relapse rate over Aubagio?*?(teriflunomide) in patients with relapsing forms of MS (RMS)[1]
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail:?investor.relations@novartis.com
- Key secondary endpoints of delaying time to confirmed disability progression were also met[1]; ?additional secondary endpoints will be presented at ECTRIMS
- Ofatumumab, a potent, fully-human antibody targeting CD20 positive B-cells, delivered sustained efficacy with a favorable safety profile[1]?
- Novartis plans to initiate submissions to health authorities by end of 2019. If approved, ofatumumab will potentially become a treatment for a broad RMS population and the first B-cell therapy that can be self-administered at home
# # #
Novartis Global External Communications E-mail:?media.relations@novartis.comAntonio Ligi Novartis External Communications +41 61 324 13 74 antonio.ligi@novartis.comEric Althoff Novartis US External Communications +1 646 438 4335 eric.althoff@novartis.com | Friedrich vonHeyl Novartis Global Pharma Communications +41 61 324 8984(direct) +41 79 749 0286 (mobile) friedrich.vonheyl@novartis.com |
Central | North America | ||
Samir Shah | +41 61 324 7944 | Sloan Simpson | +1 862 778 5052 |
Pierre-Michel Bringer | +41 61 324 1065 | Cory Twining | +1 862 778 3258 |
Thomas Hungerbuehler | +41 61 324 8425 | ||
Isabella Zinck | +41 61 324 7188 |